Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® EP Attends 2018 Dunhuang Cardiovascular Disease Forum to Display Columbus™


Dunhuang, China – From January 5 to January 6, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") attended the "Dunhuang Cardiovascular Disease Forum – the Application of 3D Navigation Technology in the Treatment of Complex Cardiac Arrhythmias" that was held in the First Hospital of Lanzhou University in Lanzhou of Gansu Province, and displayed its Columbus™ 3D EP Navigation System ("Columbus™"). During the forum, several renowned EP experts, including Professor Dening Liao of Shanghai Changzheng Hospital, Professor Bing Yang of Jiangsu Province Hospital, and Professor Feng Ze of Peking University People's Hospital, were invited to have in-depth discussion regarding hot issues of the EP field and conduct case demonstrations, which attracted wide attention from local cardiologists.
The opening ceremony was chaired by Professor Zheng Zhang, President of the First Hospital of Lanzhou University. Professor Dening Liao, Professor Bing Yang, and Professor Feng Ze delivered speeches respectively about "measures to increase the long-term success rate of pulmonary vein isolation", "radiofrequency ablation of persistent atrial fibrillation – Nanjing Procedure", and "clinical treatment strategy of ventricular tachycardia." The experts exchanged ideas on the latest advancement, new concepts, and hot topics in the EP field, which was well received by people in attendance.
During the forum, Professor Bing Yang and Professor Feng Ze were invited to perform more than 10 radio-frequency ablation procedures in treating complex cardiac arrhythmias operations as case demonstration. In particular, Professor Feng Ze in eight hours completed six radio-frequency ablation procedures in treating complex cardiac arrhythmias, including supraventricular tachycardia, premature ventricular contractions, ventricular tachycardia, atrial tachycardia, atrial flutter, and paroxysmal atrial fibrillation. The cases were well moderated by Professor Zheng Zhang, Professor Ling Ma of Lanzhou Military General Hospital as well as Professor Yali Yao and Professor Bo Yang of the First Hospital of Lanzhou University in the transmission room of the cardiac center. Experts in attendance highly recognized the excellent clinical performance of Columbus™.
Columbus™ is the first domestically developed 3D EP navigation system that features real time electromagnetic device tracking with cardiac motion compensation. It offers vivid 3D simulation of the catheter deflectable segment and accurate geometric reconstruction of intra cardiac chambers. With the help of FireMagic™ Cool 3D Irrigated Ablation Catheter that shows precise location of the catheter curve in the body, Columbus™ provides physicians with a comprehensive solution for the radiofrequency ablation treatment of complex arrhythmias. It also features powerful workstation with integrated ECG recording module, automatic 3D image segmentation of cardiac chambers with one mouse click, and accurate preoperative CT image registration and integration. Meanwhile, the system is all Chinese interface and easy to operate.
Columbus™ is the only domestically made 3D EP navigation system with the CE certificate, which fills gaps in the field of domestically made EP devices and effectively lowers the medical cost for patients. As the only domestic company that provides a complete solution of cardiac EP treatment, MicroPort® EP will continue to strive for innovation and perfection to provide better arrhythmia solutions for patients and physicians.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:Firehawk® Gains Regulatory Approval in Taiwan
[Next]:MicroPort® Signs Strategic Agreement with Neptunus Biotechnology